Liver cirrhosis represents the final stage of chronic liver disease, characterised by irreversible fibrosis and hepatocyte loss. Treatment focuses on halting progression, managing complications, and preventing decompensation. Liver transplantation remains the only cure for advanced disease; stem-cell approaches are being researched to slow or reverse fibrosis.
Management depends on the underlying cause—antiviral therapy (direct-acting antivirals for hepatitis C achieve >95% cure rates), abstinence from alcohol, immunosuppression for autoimmune hepatitis, and phlebotomy for haemochromatosis. Diuretics (spironolactone, furosemide) and sodium restriction manage ascites; beta-blockers (propranolol, carvedilol) reduce portal hypertension and variceal bleeding risk. Preventive variceal screening via endoscopy and band ligation prevents catastrophic haemorrhage. Lactulose and rifaxomicin address hepatic encephalopathy. Ursodeoxycholic acid may slow primary biliary/sclerosing cholangitis progression. Orthotopic liver transplantation is indicated for decompensated cirrhosis and hepatocellular carcinoma.
Silymarin (milk thistle) and phosphatidylcholine show mixed evidence in small trials for reducing transaminases but do not reverse established fibrosis. Herbal blends (schisandra, astragalus) are used in traditional medicine but lack robust clinical validation. Acupuncture and Traditional Chinese Medicine formulations are explored anecdotally but should never replace antiviral or immunosuppressive therapy.
Stem-cell therapies are being studied for hepatic stellate-cell inhibition and hepatocyte regeneration. Bone-marrow-derived and adipose-derived mesenchymal stem cells may reduce fibrotic inflammation and improve synthetic liver function in early clinical trials. These remain investigational and should complement, not replace, transplant evaluation. Consult candidacy criteria for suitability.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Antiviral therapy (DAAs for hepatitis C) | Standard | Strong | €10,000–25,000 | Low | None |
| Beta-blocker (propranolol, carvedilol) | Standard | Strong | €100–300/year | Low | None |
| Diuretic and sodium restriction | Standard | Strong | €200–500/year | Low | None |
| Variceal band ligation (endoscopic) | Standard | Strong | €1,500–3,000 | Medium | 1 week |
| Silymarin (milk thistle) supplementation | Alternative | Limited | €80–150/year | Low | None |
| Hepatic stellate-cell inhibition (stem-cell) | Regenerative | Investigational | €15,000–30,000 (trial-dependent) | Medium | 2–3 weeks |
| Orthotopic liver transplantation | Standard | Strong | €200,000–350,000 | High | 8–12 weeks |
Early trials suggest mesenchymal stem cells may slow or stabilise fibrosis progression, but reversal of established cirrhosis has not been proven. Transplantation remains the only definitive cure for decompensated disease.
Patients ineligible for transplant focus on preventing complications (bleeding, encephalopathy, kidney failure) and underlying-cause treatment. Stem-cell trials may offer an option; discuss with your hepatologist.
Hepatitis C requires antiviral therapy; alcoholic cirrhosis requires complete abstinence. Both benefit from portal-hypertension management and fibrosis-slowing strategies.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită